Additionally, we could hypothesis that CD133 inhibits ROS resistance through the maintenance of ROS-induced increasing xCT expression in CD133-positive HCC cells, and thereby plays a central role in resistance to liver cancer therapy. The gene discussed is PROM1; the disease is hepatocellular carcinoma.